Tolerance of high-dose (3,000 mg/day) coenzyme Q10 in ALS

被引：129

作者：

Ferrante, KL

Shefner, J

Zhang, H

Betensky, R

O'Brien, M

Yu, H

Fantasia, M

Taft, J

Beal, MF

Traynor, B

Newhall, K

Donofrio, P

Caress, J

Ashburn, C

Freiberg, B

O'Neill, C

Paladenech, C

Walker, T

Pestronk, A

Abrams, B

Florence, J

Renna, R

Schierbecker, J

Malkus, B

Cudkowicz, M

机构：

[1] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Neurol Clin Trials Unit, Boston, MA 02115 USA

[2] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Biostat,Dept Biostat, Boston, MA 02115 USA

[3] SUNY Upstate Med Univ, Dept Neurol, Syracuse, NY USA

[4] Cornell Univ, Weill Med Coll, New York Presbyterian Hosp, Dept Neurol & Neurosci, New York, NY 10021 USA

[5] Wake Forest Univ, Sch Med, Dept Neurol, Winston Salem, NC 27109 USA

[6] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA

来源：

NEUROLOGY | 2005年 / 65卷 / 11期

关键词：

D O I：

10.1212/01.wnl.0000187070.35365.d7

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

An open-label dose-escalation trial was performed to assess the safety and tolerability of high doses of coenzyme Q10 (CoQ10) in ALS. CoQ10, a cofactor in mitochondrial electron transfer, may improve the mitochondrial dysfunction in ALS. In this study, CoQ10 was safe and well tolerated in 31 subjects treated with doses as high as 3,000 mg/day for 8 months.

引用

页码：1834 / 1836

页数：3

共 9 条

[1] Mitochondria and the pathogenesis of ALS [J].